Autres langues Emyria Limited

Actions

Marché Fermé - Australian S.E. Autres places de cotation 07:55:19 26/04/2024			Varia. 5j.	Varia. 1 janv.
0,049 ^AUD	-3,92 %		-9,26 %	-5,77 %

10/04	Emyria lance l'Empax Center	MT
05/04	La deuxième psychiatre d'Emyria reçoit le statut de prescripteur autorisé de la TGA	MT

Emyria to Raise AU$2.3 Million via Placement	23/04
Emyria opens Empax Centre to target care gaps in resistant PTSD	10/04
Emyria Launches Empax Center	10/04
Emyria's Second Psychiatrist Receives Authorized Prescriber Status from TGA	05/04
Emyria Signs Study Agreement for MDMA-Assisted Therapy; Shares Up 7%	03/04
Emyria Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02
Emyria Secures AU$2.5 Million R&D Tax Rebate for Fiscal Year 2023	15/01
Australian Medical Regulator Grants ‘Authorized Prescriber’ Status to Emyria’s Specialist Psychiatrist; Shares Soar 19%	10/01
Emyria welcomes top healthcare leader as chairman	22/11
Emyria Limited Appoints Greg Hutchinson as Director	21/11
PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules	15/11
Emyria Limited Announces Board Changes	12/11
Emyria hails strong growth in clinical billings	26/10/23
Emyria Secures Canadian Regulatory Clearance to Import MDMA to Australia; Shares Fall 3%	19/10/23
Emyria Begins MDMA Therapy Trials on PTSD Patients	10/10/23
Emyria set to begin MDMA study after securing local supply	26/09/23
Emyria Secures Local Supply of Psychedelic Drug for Upcoming Trial; Shares Rise 3%	21/09/23
Emyria Completes Pax Center Acquisition	13/09/23
Emyria Limited completed the acquisition of The Pax Centre from Glenroyale Pty Ltd and Vivo (WA) Pty Ltd.	13/09/23
Emyria provides unique combination of drug development and therapy delivery	07/09/23

Aucun résultat pour cette recherche